Login to Your Account



Amylin Taking Lilly to Court Citing Breach in Byetta Deal

By Jennifer Boggs


Tuesday, May 17, 2011
A diabetes drug agreement inked earlier this year between Eli Lilly and Co. and Boehringer Ingelheim GmbH has become a source of dispute in Lilly's so-far-lucrative nine-year partnership with Amylin Pharmaceuticals Inc. for glucagon-like peptide 1 (GLP-1) receptor agonist Byetta (exenatide).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription